In SCLC, ongoing and upcoming SCLC immunotherapy clinical trials include combinations of ICIs with novel targeted combinations such as PARP inhibitors, AKT1 inhibitors, and ATR inhibitors, and new immune‐based therapeutic strategies such as CART and BiTES, and so on, are expected to achieve good results. Here, ATR is linked to small cell lung carcinoma.